Results 131 to 140 of about 7,686 (201)

Lipoprotein (a), an independent cardiovascular risk marker [PDF]

, 2016

core   +1 more source

Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction <i>via</i> pharmacophore-based virtual screening, molecular dynamics simulations and <i>in vitro/vivo</i> evaluation. [PDF]

J Enzyme Inhib Med Chem
Wu W, Yang S, Liu J, Wang Y, Pan D, Zhou Y.   +5 more
europepmc   +1 more source

Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis. [PDF]

BMC Cardiovasc Disord
Kao G, Chen C, Zhang Y, Xu Y, Xu G.
europepmc   +1 more source

PCSK9 inhibition: the way forward in the treatment of dyslipidemia [PDF]

core   +1 more source

Lipoprotein(a) in nephrological patients [PDF]

, 2017
Bernd Hohenstein
core   +1 more source

Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Ding W, Sun L, Shi Y, Tian L.
europepmc   +1 more source

The Economic Burden of Atherosclerotic Cardiovascular Disease in the Kingdom of Saudi Arabia. [PDF]

Saudi Med J
Alasnag M, Tash A.
europepmc   +1 more source

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis. [PDF]

Front Pharmacol
Luo B, Sun Z, Luo H.
europepmc   +1 more source

New drugs: Evolocumab [PDF]

Australian Prescriber, 2016
openaire   +1 more source

Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention. [PDF]

J Clin Med
Forzano I, Florimonte D, Narciso V, Canonico ME, Castiello DS, Manzi L, Cristiano S, Spinelli A, Vallone DM, D'Alconzo D, Semplice F, Paolillo R, Giugliano G, Cesaro A, Gragnano F, Calabrò P, Esposito G, Gargiulo G.   +17 more
europepmc   +1 more source